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The primary question facing researchers who intend to employ elderly
human subjects is whether their subjects' advanced age requires that the pro-
tection of their autonomy be accomplished in some manner that is different
from that employed to protect other subjects. Answering this question will
require an analysis of whether elderly subjects have a greater or lesser inter-
est in autonomy than do others who might be subjects in human research,
and whether it is more or less important to protect them from potential re-
search abuse. This article will suggest that the elderly may possess several
attributes that require that they be employed as research subjects only when
the selection process and research design compensate for those attributes.
The most troubling area for medical investigators who regularly employ
elderly subjects is the propriety of conducting research upon patients suffer-
ing from senile dementia, particularly senile dementia of the Alzheimer's
type. This devastating illness has developed a high political profile over the
past several years, causing a great deal of research interest in and, more
importantly, research funding for the study of this disease. As the elderly
population continues to grow and develop into a powerful political lobby,
the interest in senile dementia among the medical community will continue
to increase. While the vast majority of the elderly do not suffer from senile
dementia, most Alzheimer's patients are elderly. The presence of this dis-
ease affects the ability of its sufferers to give consent, and often renders it
impossible to obtain consent that would be valid under standard accepted
principles. On the other hand, the disease is a terrifying one, often research
can be done only upon those suffering from the disease, and failure to do this
research may condemn future generations to a devastation that could be
overcome.
* Professor of Law, University of New Mexico School of Law, B.A., Stanford Univer-
sity; J.D. magna cum laude, Harvard University.
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1.
Although the institution of informed consent has been justified on many
different grounds' - it promotes trust and respect for the medical profes-
sion,2 for example - its principal purpose is the protection of the autonomy
of those undergoing a medical procedure, and it is the primary social institu-
tion established to protect the autonomy of patients and subjects.' The doc-
trine is explicitly founded upon the notions that what one does with one's
body is a personal choice,4 and that the law, along with other social institu-
tions, must act to protect that privacy interest.' The doctrine of informed
consent applies to everyone who may undergo any medical procedure,6 and
it applies whether the procedure is denominated "treatment" or "research." 7
In fact, it developed directly from the common law "consent" defense to a
battery (any unconsented harmful or offensive touching)8 and thus applies to
any physical touching of one person by another.9
Of course, the doctrine of informed consent, as any other legal doctrine
designed to protect freedom, has costs.10 Researchers view informed con-
sent as a barrier to experimentation," if not an insidious plot designed to
deny them the pursuit of their chosen profession. Indeed, the necessity of
informed consent is a barrier to research in some cases; it makes almost all
research slightly more inconvenient and it renders some research almost im-
possible.12 For example, if no proxy consent is available for the most se-
1. See J. LUDLAM, INFORMED CONSENT (1978).
2. PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE
AND BIOMEDICAL AND BEHAVIORAL RESEARCH, MAKING HEALTH CARE DECISIONS 36, 44
(1982). (Hereinafter cited as MAKING HEALTH CARE DECISIONS).
3. Meisel, The 'Exceptions' to the Informed Consent Doctrine: Striking a Balance Be-
tween Competing Values in Medical Decisionmaking, 1979 WIS. L. REv. 413, 414 (1979).
4. See, e.g., Schloendorffv. Society of New York Hosp., 211 N.Y. 125, 129-30, 105 N.E.
92, 93 (1914).
5. J. KATZ, EXPERIMENTATION WITH HUMAN BEINGS 540-88 (1972).
6. R. LEVINE, ETHICS AND REGULATION OF CLINICAL RESEARCH 69-116 (1981).
7. Id. Note that the distinction between treatment and research is not always clearcut.
Indeed, it is likely that the vast majority of research done in the United States is viewed by the
investigator as being, at least in part, therapeutic.
8. W. PROSSER, HANDBOOK OF THE LAW OF TORTS § 18 at 102, § 32 at 165 (4th ed.
1971). See generally Pernick, The Patient's Role in Medical Decisionmaking: A Social History
of Informed Consent in Medical Therapy, in 3 MAKING HEALTH CARE DECISIONS supra note
2, at 1-35 (app.).
9. See PROSSER, supra note 8, § 10 at 35, § 32 at 165.
10. MEISEL, WHAT WOULD IT MEAN TO BE COMPETENT ENOUGH TO CONSENT OR
REFUSE PARTICIPATION IN RESEARCH: A LEGAL OVERVIEW COMPETENCY AND IN-
FORMED CONSENT 32-71 (N. Reatig ed. 1981).




verely ill and thus, at least for Alzheimer's patients, the most clearly
incompetent, no research will be legally pursued to find treatment for the
most severe type of dementia. The doctrine of informed consent, at least to
the extent it does not permit proxy consent, would render that research im-
possible. The consequence of such a policy of informed consent might be
that no course of treatment could be developed for this disease, and that
consequence would surely be a serious and frightful one. On the other hand,
if we do not respect the doctrine of informed consent, even for those suffer-
ing the most severe form of senile dementia, we will permit the medical con-
scription of the senile and approve a process that forces them to serve a
progress they may neither desire nor care about.
The question is not whether we should draft subjects to serve medical
progress but rather, who is a "true" volunteer? 3 How certain must a re-
searcher be that a subject truly wishes to participate in a research protocol
before he accepts his consent? The answer to that question rests in the pa-
rameters of the doctrine of informed consent that will be applied to research
subjects. That doctrine is itself a consequence of social policy that must
weigh, on the one hand, the values of autonomy and clear affirmative con-
sent, and, on the other hand, the value of research that may never be carried
out if we require "perfect" consent from competent medically-trained
subjects.
In weighing the value of research and the value of autonomy, this society
has chosen to err towards protecting one's right to control one's own body. "
We are heirs to the Nazi experimentation, 5 the Tuskegee Institute syphilis
study, '6 as well as the Jewish Chronic Disease Hospital cancer implant,'
7
and we can easily see the enormity of neglecting to protect individual sub-
jects' autonomy. Alas, we never see the foregone results of research that was
not undertaken. Those developments may have been especially significant in
senile dementia of the Alzheimer's type, where the costs of the illness - in
emotional, physical, and financial terms - are tremendous.'
Balancing the interests in encouraging research and protecting individual
autonomy is clearly a matter of social policy. As the Senate Committee on
the Judiciary was told in 1974:
13. Ratzan, Being Old Makes You Different: The Ethics of Research with Elderly Subjects,
HASTINGS CENTER REP., Oct. 1980, at 34. See generally, Protection of Human Subjects, 45
C.F.R. § 46 (1983).
14. Supra note 2, at 44-45.
15. 1 NUREMBERG CODE FOR TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG
MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW No. 10 XVI (1949).
16. JONES, BAD BLOOD (1982).
17. KATZ, supra note 5, at 9-65.
18. Ratzan, supra note 13.
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The problem of ethical experimentation is the product of the un-
resolved conflict between two strongly held values: the dignity and
integrity of the individual, and the freedom of scientific inquiry.
Professionals of many disciplines, and researchers especially, exer-
cise unexamined discretion to interfere in the lives of their subjects
for the sake of scientific progress. Although exposure to needless
harm and neglect of the duty to obtain the subject's consent have
been generally frowned upon in theory, the infliction of unneces-
sary harm and infringements on informed consent are frequently
accepted in practice as the price to be paid for the advancement of
knowledge. How have investigators come to claim this sweeping
prerogative? If the answer to this question is that society has au-
thorized professionals to choose between scientific progress and in-
dividual human dignity and welfare, should not 'society' retain
some control over the research enterprise? 9
In designing a doctrine of informed consent that gives proper weight to the
subject's autonomy and to values of research, there first must be a determi-
nation of who is responsible for the development of social policy. Surely
such policy decisions must not be left to investigators themselves, who are
(and, perhaps, should be) prejudiced in favor of research. It would not be
surprising if they considered their professional endeavor to be of even greater
importance than would the rest of the community - after all, they have
dedicated their professional lives to research.
There are, however, many other social institutions which contribute to the
development of the requirements of informed consent, and, thus, to the bal-
ancing of the value of experimentation and the human dignity which might
be put at stake by such experimentation. These institutions include the in-
formal control of the medical profession's social customs, which are devel-
oped primarily in the realm of physicians providing therapy, not doing
research.2 ° In addition, formal policies emerge from hospital regulations.2 1
The restrictions this community places upon experimentation are the conse-
quences of several of these institutions. For example, the consent require-
ments of the Food, Drug and Cosmetic Act are reflected in the regulations
19. Individual Rights and the Federal Role in Behavior Modification, (Materials Relating
to HEW Policies Concerning Behavior Research): A Study Prepared by the Staff of the Sub-
committee on Constitutional Rights of the Committee on the Judiciary, United States Senate,
1974, at 109. This particular statement was provided by the Tuskegee Syphilis Study Ad Hoc
Advisory Panel.
20. Levine, The Boundaries Between Biomedical of Behavior Research and the Accepted
and Routine Practice of Medicine, in THE BELMONT REPORT, ETHICAL PRINCIPLES AND
GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH 1, 6-8 (1978).
21. LEVINE, supra note 6, at 259-91.
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which establish institutional review boards.22 These regulations, in turn,
give rise to hospital regulations and policies. All of these sources - the
federal statute, the federal regulations, and the local institutional review
board policies, along with the state law of informed consent and the informal
social customs of local physicians - govern each case.
Obviously, the interests protected by the doctrine of informed consent
need not be protected by the law alone. Perhaps the best way to serve the
interests of the doctrine of informed consent would be to educate medical
students so that they develop a high regard for the autonomy of their pa-
tients and subjects.23 Physicians and investigators have regularly com-
plained that the legally imposed standards for informed consent are rigid,
inflexible, and leave no room for discretion in an area that so plainly requires
sensitivity to individual cases.24 The National Institutes of Health have con-
vened a conference to discuss the developments of standards for investiga-
tors who seek consent for participation in research from subjects in protocols
studying Alzheimer's disease." To the extent that the standards provide
successful informal control over those who would potentially abuse subjects,
they will obviate the need for the formal development of a positive law of
informed consent in this narrow area.
II.
The doctrine of informed consent requires that before any person be sub-
jected to any medical procedure that person must be informed about the
procedure and its alternatives, give voluntary consent to undergo that proce-
dure, and be competent to give that consent.26 Without this consent, medi-
cal conduct, whether research or treatment, cannot be undertaken.
Although several early informed consent malpractice cases involved pro-
cedures described by courts as "experimental," '27 none of them involved
22. 45 C.F.R. 46.101-03 (1981).
23. Blackwell, Drug Therapy - Patient Compliance, 289 NEW ENGo. J. MED. 249, 252
(1973). See also Kaufmann, Medical Education and Physician-Patient Communication, in 3
MAKING HEALTH CARE DECISIONS, supra note 2, at 117-41 (app.); Oratz, Achieving Aesthetic
Distance: Education for an Effective Doctor-Patient Relationship, 3 MAKING HEALTH CARE
DECISIONS, supra note 2, at 143-73 (app.).
24. "The right to base one's consent on proper information is effectively vitiated for those
with fears, apprehensions, religious beliefs, or superstitions outside the mainstream of society."
McPherson v. Ellis, 305 N.C. 266, 273, 287 S.E.2d 892, 897 (1982).
25. NIH, Conference on Senile Dementia of the Alzheimer's Type and Related Disease -
Ethical and Legal Issues Related to Informed Consent, Bethesda, Maryland, Nov. 22-23, 1981.
26. See, e.g., NUREMBERG CODE, supra note 15. See also MAKING HEALTH CARE DECi-
SIONS, supra note 2.
27. See Slater v. Baker & Stapleton, 95 Eng. Rep. 860 862, (1767) and subsequent notes
reprinted in KATZ, supra note 5, at 526-29.
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otherwise properly scientifically defensible research. In fact, litigation over
informed consent has generally arisen out of instances of therapeutic treat-
ment, not research. Thus, we ought to determine whether the doctrine of
informed consent should be treated differently in a research context from the
way in which it would be treated in the traditional therapeutic context.
Indeed, given the grand social function of medical research, one might
argue that the doctrine of informed consent should be less strictly applied to
research subjects than to patients seeking therapeutic treatment which has
entirely private benefit. No legal authority has suggested that the social in-
terests in having research performed make the doctrine of informed consent
less significant in this context, however.28 In fact, the doctrine of informed
consent may be of greater importance in the research context because there
might be a greater potential for medical deviousness among researchers, and
that might require the community to be more protective of subject
autonomy.29
There are four reasons for concluding that the doctrine of informed con-
sent is a more necessary check against physican abuse in research than in
therapeutic treatment . First, a physician may be more likely to be moti-
vated to lie to get consent from a research subject than from a patient in
therapy. While therapeutic treatment is in the interests of the patient, re-
search is in the interest of the society - and in the interest of the physician,
whose academic tenure and professional advancement may depend on run-
ning a research protocol with statistically proper subject participation. Any
potential investigator misrepresentations can be limited by requiring that the
subject's informed consent be given in writing, and that the written instru-
ment include all of the information necessary to make the consent "in-
formed." Indeed, federal regulations require that informed consent in the
research context be obtained and reserved in writing,30 even though the
common law does not require that informed consent for therapeutic treat-
ment be in writing.3"
Second, the "therapeutic privilege" which permits physicians to omit
otherwise necessary information from that provided to a patient when pro-
viding that information would be harmful to the patient, does not apply to
pure research.32 Since pure research is not therapuetic, there is no reason
for a therapeutic privilege. Third, we are skeptical of acts which appear to
be motivated by unabashed altruism. A patient who consents to necessary
28. See Protection of Human Subjects, 45 C.F.R. § 46 (1983).
29. LEVINE, supra note 6, at 93, but see contra, at 94.
30. 45 C.F.R. § 46.117 (1983).
31. See, e.g., Maercklein v. Smith, 129 Colo. 72, 80, 266 P.2d 1095, 1099 (1954).
32. LEVINE, supra note 6, at 113.
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medical treatment is perceived as doing that which any reasonable person
would do; a person who consents to a medical process so that society's
knowledge can be enhanced is not perceived as acting quite so naturally.
33
Thus, we view consent to participate in research as being more suspect than
consent to therapy.
Finally, our recent history gives us more worry about the abuse of re-
search than the abuse of medical therapy. There are few celebrated exam-
ples of medical bad faith in obtaining consent to theraputic treatment; from
the time of the Nazi atrocities (and the Tuskegee syphilis study) our history
provides us with ample evidence of medical bad faith in obtaining consent to
research. 4
There are additional reasons for being especially careful to protect the
autonomy of subjects of research investigating diseases most common in the
elderly - and especially senile dementia of the Alzheimer's type. First, such
research is likely to be wide ranging and unfocused. We do not know what
Alzheimer's disease is, and we cannot adequately measure its severity.35 It is
difficult to tell when it is improving and when it is becoming worse. 36 These
difficulties are compounded by the fact that the earliest effectiveness trials of
drugs designed to treat senile dementia will have to be conducted with
human subjects. We may be able to learn about the side effects of proposed
treatment by testing the drugs in laboratory rats, but it is unlikely that we
will learn anything about the drug's efficacy by applying it to senile labora-
tory animals.
Second, the treament of senile dementia may already be overmedicalized
and increased research in this area may only exacerbate the problem.3 7 Con-
tinuing focus on medical research to find a treatment for Alzheimer's disease
may create a core of specialists who feel obliged to provide medical treat-
ment which is a severe intrusion on their patient's autonomy and yet offers
little in the way of comfort or cure. The existence of Medicare and other
reimbursements for physician services makes it likely that private enterprise
33. Tverksy & Kahneman, The Experiment that Wasn't: The Framing of Decision and the
Psychology of Choice, 211 Sci. 453-58, (1981).
34. See supra notes 19-21.
35. Jarvik, Diagnosis of Dementia in the Elderly: A 1980 Perspective in I ANN. REV. OF
GERONTOLOGY & GERIATRICS 130-203 (1980).
36. Crook, Psychometric Assessment in the Elderly in PSYCHIATRIC SYMPTOMS AND COG-
NITIVE Loss IN THE ELDERLY 207-720 (A. Raskin & L. Jarvik eds. 1979).
37. Schwartz, Development of Psychopharmacologic Drugs for the Cognitively and Emo-
tionally Impaired Elderly: Some Ethical and Legal Considerations, 17
PSYCHOPHARMACOLOGY BULL. 64 (1981).
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will rush to provide medical care that can be sold to the elderly population. 38
For example, one would expect the drug companies to be willing to invest in
research to develop drugs which could be approved for "selected symptoms
in elderly patients. . . mood, depression, confusion, unsociability, and diz-
ziness."' 39 Hydergin, for example, generated nineteen million dollars in sales
in 1979 despite its novelty and highly controversial nature.'
Physicians are willing to employ these minimally effective treatments for
senile dementia because they allow the physician to do something to treat
this terrifying disease. Both the physician and the patient's family are more
likely to believe that a senile patient is getting good medical care if something
affirmative is being done, even if it is barely effective or completely ineffec-
tive.4 ' Of course, no therapy is harmless. Any treatment developed for
Alzheimer's disease is likely to have side effects. In addition, any treatment
will impose another medical burden on a class already significantly burdened
by medication and other regular medical treatments. This over-medication
may mask other symptoms which would show the illness to be one of the
reversible diseases often wrongfully diagnosed as senile dementia of the
Alzheimer's type.42 Some physicians estimate that 35% of those diagnosed
as suffering from senile dementia are actually suffering from other diseases
which could be medically treated.43 Finally, as the Public Citizen Research
Group reported to the Psychopharmacologic Drugs Advisory Committee of
the Food and Drug Administration meeting in March of 1981:
[T]hese drugs may give the doctor a false sense of security. Results
of drug studies today make it questionable, at best, whether they
offer any meaningful clinical benefits. Yet, as the British Medical
Journal noted, 'by making the doctor feel that he is doing some-
thing, the administration of these drugs may actually deflect from
him the really important tasks: providing the patient and family
with sympathy, practical advice and social support'.'
Just as the disease process being studied may affect our analysis of -the
importance of obtaining informed consent from potential subjects, so should
the classes from which the subjects will be derived. The subjects of research
38. Id See also Shoulson, Rational Pharmacotherapy in Dementia: Hazards of 'Vadodi-
lator Therapy' in L. LASAGNA, CONTROVERSIES IN THERAPEUTICS 368-73 (1980).
39. Statement of Eve Bargmann, M.D., before the FDA Psychopharmacologic Drugs Ad-
visory Committee, Mar. 23, 1981.
40. Id.
41. Schwartz, supra note 37.
42. Jarvik supra note 35.
43. Hollister, Are Drugs Useful for Treating Senile Dementia? CONTROVERSIES IN THER-
APEUTICS, supra note 38, at 362.
44. Supra note 39 at 5.
Informed Consent
in senile dementia will be cognitively or emotionally impaired, because that
impairment is one of the defining characteristics of the disease.45 In addi-
tion, most of the subjects are likely to be elderly, and many will be institu-
tionalized, either in nursing homes or in mental institutions. In fact, a great
number of drug studies investigating potential treatments for senile dementia
have been conducted among institutionalized patients.'
The elderly, those suffering from senile dementia, and those institutional-
ized in nursing homes or in mental institutions are perceived as being sickly,
unproductive, and unhappy.47 The stereotype of potential subjects for
Alzheimer's disease studies would attribute to them very little reason to live.
Because researchers may attribute a low value to the lives and health of these
subjects, it may be especially important that we be vigilant in protecting
their autonomy from intended or unintended abuse.
In determining how the doctrine of informed consent ought to be shaped
in this area, we must recognize not only the tension between the interest in
protecting the autonomy of subjects and the interest in curing a dreaded
disease, but also the tension between protecting the autonomy of potential
subjects by preserving their right to choose for themselves, and protecting
the autonomy of those subjects by removing the subtle and unrecognized
pressures and coercions that may dictate their choice. An elderly, ill, and
institutionalized person may be losing control over most of the most com-
monplace activities of everyday life.4" Most of the autonomy that person
retains may be invested in his control over his medical care.49 Indeed, it
may be a much greater intrusion on that patient's autonomy to remove his
power over his own medical care (and to remove his right to consent to be a
research subject) than it would be to remove that power from another person
who maintains control over other aspects of his life.
III.
For consent to be legally valid, it must be informed, voluntary, and given
by a competent subject. The last section of this article explains the reasons
for evaluating these requirements carefully where the medical conduct is re-
45. See supra note 36. See also Horn, Psychometric Studies of Aging and Intelligence, in 2
AGING 19-44 (1975)
46. Supra note 14.
47. McTavish, Perceptions of Old People: A Review of Research Methodologies and Find-
ings, 11 THE GERONTOLOGIST 90-101 (1971). See also R. BUTLER, WHY SURVIVE? BEING
OLD IN AMERICA (1975).
48. Lawton, Do Elderly Reseach Subjects Need Special Protection? Psychological Vulner-
ability, 2(8) IRB: A JOURNAL OF HUMAN RESEARCH 5-7 (1980).
49. Harper, Paternalism and the Elderly in AGING AND THE ELDERLY 321-39 (Spicker,
Woodward & Tassell eds. 1978).
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search rather than treatment. In this section, the article will briefly define
each of those requirements and then attempt to determine whether the sub-
ject's status as an elderly person, as a senile dementia patient, or as a resident
of a nursing home is relevant in analyzing whether that person's consent is
properly informed and voluntarily given, and whether that person is compe-
tent to provide that consent.
Although the definition of what constitutes truly "informed" consent has
been the subject of an extraordinary amount of academic writing and judicial
evaluation," most courts now agree that the one giving consent must be
provided with as much information about the proposed medical procedure,
the alternative procedures, any research which is involved, and the risks and
benefits of each of these, as a person in the position of the proposed subject
would require in order to make a reasoned decision.5 Of course, the infor-
mation that must be provided will vary from research protocol to research
protocol, and from subject to subject within each protocol. In addition, the
information may have to be presented to different subjects in different ways;
the information has no meaning, practically or legally, if it is not presented
in such a way that the subject actually does understand it.52 Providing too
little or too much information may render the consent uninformed if it mis-
leads the one whose consent is sought." For example, both failing to ex-
plain a likely outcome and explaining in great detail a very unlikely result
may equally mislead the subject.54
The potential subject's status as an elderly person may affect the nature of
truly informed consent." In addition, those studies indicate that older peo-
ple have a slower reaction time and require more time to process complex
information than do otherwise similarly situated younger people.56 Thus,
even when an investigator might expect a younger person to be able to con-
sent immediatley upon hearing the risks and benefits of a medical procedure,
50. See the discussion of these definitions in Maisel & Kabnick, Informed Consent to Med-
ical Treatment: An Analysis of Recent Legislation. 41 U. Prrr. L. REV. 409-10 (1980); A.
RosoFF, Informed Consent (1981).
51. See, eg., Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972); Cobbs v. Grant, 104
Cal. Rptr. 505, 502 P.2d 1 (1972).
52. H.R. TURNBULL ET. AL., CONSENT HANDBOOK (1977).
53. Pernick, supra note 8, at 71.
54. Id
55. Horn, supra note 45. See also Botwinick, Behavioral Process, 2 AGING 1-18 (1975);
Cohen & Wu, Language and Cognition During Aging, 1 ANN. REV. OF GERONTOLOGY &
GERIATRICS 71-96 (1980); Craik, Age Differences in Human Memory, in HANDBOOK OF PSY-
CHOLOGY OF AGING 384-417 (J. Birren & R. Schale eds. 1977); Hiens & Fozard, Memory and
Aging: Relevance of Recent Developments for Research and Application, 1 ANN. REV. OF GER-
ONTOLOGY & GERIATRICS 97-120 (1980).
56. Ratzan, supra note 13; Lawton, supra note 48, at 5.
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he ought to provide older people with more time to process that information.
It may be important to temporarily separate the informing process from the
consent process when those who are sought to consent are elderly, even if
there is no need to do so under other circumstances.
Older people are more likely than others to have hearing or vision impair-
ments,5 7 and thus any information provided to them ought to be offered by
those sensitive to these potential difficulties. One with impaired vision ought
not be asked to read and sign the fine print of a bureaucratically designed
consent form. Similarly, the oral description of the risks and benefits of a
particular procedure might be inappropriate for one with a hearing problem.
Also, older people may be less familiar with bureaucratic requirements than
are younger people and they may be less comfortable with formal written
documentation than others would be.5 8 Obtaining truly informed consent
from older people may require that the process be more informal, more per-
sonal, simpler, and more drawn out than it need be in other cases.
Finally, some substantive information that is highly significant to younger
people may be irrevelant to those who are older. For example, the fact that
a subject in a particular research protocol is exposing himself to a disease
with horrible consequences after a forty-year latency period will be far less
significant to someone who is ninety years old than to a twenty year old
potential subject. In providing information to a subject of a research proto-
col, the investigator must determine what information will be significant to
the potential subject, not what information would be significant to the inves-
tigator if he were to be a subject.
A proposed subject's status as a patient with senile dementia may also
affect the nature of what constitutes truly informed consent. Memory loss is
a symptom often associated with Alzheimer's disease. Informed consent has
no meaning unless the proposed subject actually understands the proposed
medical process and its risks, benefits, and alternatives at the time the con-
sent is given. Thus, consent is not informed if it is given after the proposed
subject has forgotten the risks and benefits that were described to him, even
if he fully understood those risks and benefits at one time. Any research
conducted upon senile subjects ought to be carefully monitored to assure
that the consent is obtained when the proposed subject fully understands the
risks and benefits.
Consent is voluntary only if it is provided freely, without undue induce-
ment, without the fear of the deprivation of alternative treatments or any
57. Schwartz, supra note 37.
58. Id
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other reprisal, and without significant social pressures. 59 Although no per-
son can be free of all outside influence, consent is more likely to be truly
voluntary when the effect of those pressures is minimized.
A patient suffering from senile dementia is likely to be very dependent on
his family, physicians, and caretakers.6' This dependency which is like that
suffered by others with serious illness, makes it much more difficult for him
to provide truly voluntary consent. If the Alzheimer's disease patient be-
lieves that privileges might be limited or revoked or the quality of his care
will be altered if he does not consent, his consent surely would not be
voluntary.
The dependency which makes voluntary consent more difficult to obtain
for senile dementia patients is exacerbated in the institutionalized and the
elderly. Half of the institutionalized elderly need help in walking, bathing,
toileting, and dressing.61 They are entirely dependent upon the nursing
home administration for the most basic daily life functions. They are cer-
tainly good candidates for coercion by that administration. Indeed, they
generally recognize that they have little control over their environment and
their "learned compliance" may cause them to agree to anything apparently
favored by those who control their lives.62 In addition, half of the institu-
tionalized elderly have no living relatives, and a great number have very
little social contact.63 Many may "volunteer" to participate in research so
that they will have an opportunity for regular social contact with the investi-
gator. Consent given by one who is desperate for that social contact is no
less coerced than the consent that would be given by a prisoner hoping to be
released early because of his participation as a research subject or the con-
sent given by an involuntary resident of a mental institution hoping that his
participation will cure him, thus making him candidate for release. Indeed,
it is the apparent vulnerability of nursing home residents that led the De-
partment of Health, Education and Welfare to include them as among those
"Institutionalized as mentally disabled" for purposes of the proposed Regu-
lations on Research Involving Those Institutionalized as Mentally Dis-
abled." Of course, these regulations were never promulgated in final form.
From the investigator's point of view, elderly nursing home residents are
nearly perfect research subjects - they are easy to find, easy to control, and
59. TURNBULL, supra note 52, at 10-11.
60. Lawton, supra note 48.
61. Id. at 7.
62. Ratzan, supra note 13, at 35-37.
63. Lawton, supra note 48, at 7.
64. See Proposed Regulations on Research Involving Those Institutionalized as Mentally
Disabled, 43 Fed. Reg. 53950, 53954 (1978). These regulations were never adopted.
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easy to follow. Their records are centrally maintained and easily accessed.
The fact that they are so regularly sought out as research subjects, the fact
that they are so convenient as research subjects, and the fact that they are
under considerable presure to participate as subjects when they are asked to
do so ought to cause us to carefully scrutinize the voluntariness of their con-
sent to participate in formal research.
There is no clear and generally accepted legal definition of competency for
purposes of giving consent to a medical procedure. Every adult is presumed
to be competent for all purposes unless he is shown to be otherwise.65 For
that showing to have legal significance, generally it must take place in a
judicial proceeding which results in a formal order.66 In most jurisdictions
the courts will inquire as to whether the subject has the capacity to ration-
ally perform, at some minimal level, the tasks expected of one carrying out
the affairs of everyday life.67 If he possesses that capacity, he will not be
declared incompetent for any purpose.68 If he does not possess that capac-
ity, he will be declared incompetent for every purpose and a guardian will be
appointed to act on his behalf.69 Mere residency in a nursing home is never
sufficient to render one legally incompetent, and residency in a mental insti-
tution is generally insufficient to render one legally incompetent.70
The law is slowly recognizing that it is senseless to require that compe-
tency determinations be "all or nothing" decisions which apply to the entire
range of decisions one might be required to make.7' Obviously, one might
be competent to understand some choices and make some decisions even if
one cannot understand other choices and make other decisions. Thus, some
jurisdictions, either by statute or judicial determination, permit individuals
to be declared incompetent to make particular decisions and yet allow those
individuals to maintain their right to make other kinds of decisions.
First, a subject's competency cannot depend on that subject's adoption of
a socially preferred set of values. The mere fact that an older person, a senile
person, or a person institutionalized in a nursing home has a different set of
65. Rosoff, supra note 50.
66. Id at 234-36.
67. TURNBULL, supra note 52, at 6-8.
68. Id
69. Id
70. Rosoff, supra note 50, at 236-39. See also Annas, Glantz, & Katz, Law of Informed
Consent in Human Experimentation. Institutionalized Mentally Infirm, in NATIONAL COM-
MISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL
RESEARCH, 70 REPORT AND RECOMMENDATIONS: RESEARCH INVOLVING THOSE IN-
STITUITONALIZED AS MENTALLY INFIRM 3-1 (app.) (1978); Allen, Ferster & Weihofen,
MENTAL IMPAIRMENT AND LEGAL INCOMPETENCY 46-50 (1968).
71. Alexander, Premature'Probate: A Different Perspective on Guardianship for the Eld-
erly, 31 STAN. L. REv. 1003-33 (1979).
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values from that person had when he was younger is not relevant to the
determination of whether that subject is incompetent. Older people may be
less risk (adverse) than younger people, for example, and that fact surely
should not affect their competence to make formal legal determinations.
In addition, older people may put a higher value on comfort and the
avoidance of inconvenience, and a lower value on avoiding life-threatening
illnesses or injuries than the rest of us. 2 Indeed, some studies indicate that
older people apply problem-solving methods that are different from those
they applied when they were younger. 3 These factors are not relevant to a
determination of their competency to consent to participation in research.
Of course, competency is always an issue when a prospective subject suf-
fers from senile dementia. The mental incapacity that may render one in-
competent is always present, in one degree or another, when senile dementia
is present. Generally, the more severe the disease the less likely it is that a
prospective subject will be competent to give consent. In any case, the men-
tally incapacitating consequences of senile dementia may vary from time to
time in a single patient.7 4 A patient who is occasionally competent can le-
gally give valid consent only if that consent is provided during a competent
period." Whether that consent is so durable as to be valid even when the
subject is no longer competent presents another, yet unresolved question.
Considerations of autonomy would seem to suggest that such a consent gen-
erally should survive subsequent incapacity of the patient.
Just as the law has reached no consensus on what constitutes competency,
it has similarly reached no consensus on who ought to make that determina-
tion, initially or eventually.76 Obviously, if the subject is incompetent he
must also be incompetent to determine his competency. The researcher
should not be allocated the authority to make that determination, because
the researcher has an interest in seeing that the research is done, and thus
finding the prospective subject competent if he would then consent, and in-
competent if he would not. The proposed but unadopted Regulation on Re-
search Involving Those Institutionalized as Mentally Disabled proposed that
72. Tibbles, Medical and Legal Aspects of Competency as Affected by Old Age in SPICKER,
supra note 49, at 127-51.
73. Rabitt, Change in Problem Solving Ability in Old Age in HANDBOOK OF THE PSY-
CHOLOGY OF AGING, supra note 55, at 606-25.
74. Ratzan, supra note 13, at 37-39.
75. Schwartz, supra note 37.
76. N. Reatig, New HHS Regulations and Psychiatric Research: Guidelines for Informed
Consent with Persons of Uncertain Competence. (Presented at the Symposiom on the Future
of Psychiatric Research: Practical Problems at the Annual Meeting of the American Psychiat-
ric Association, May 11, 1981).
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a "consent auditor" make this determination,77 and others have suggested
that physicians independent of those doing the research make the determina-
tion.7 Until an alternative is developed, the current unwieldy legal require-
ment that each person be treated as legally competent unless that person is
found to be incompetent by a court after a formal judicial hearing is likely to
prevail. Further, until an alternative is adopted, researchers and physicians
will continue to act at their peril when they obtain consent from either the
subject or the subject's family if the subject is apparently incompetent but
has not been declared legally incompetent.
IV.
If a proferred consent is not properly informed, that defect can be reme-
died by providing the prospective subject with proper information. If a
proferred consent is not voluntary, that defect can be overcome by removing
the coercion upon the subject. If the patient is not competent, however,
there is no way to make the patient competent. Thus, when the competency
element is the one that is lacking and only under those circumstances, the
courts have sometimes permitted proxy consent to be offered by one author-
ized to act on behalf of the proposed subject.7 9 Unfortunately, perhaps,
there is very little support in the law for the notion that anyone can act on
behalf of an adult without having been appointed by a court to do so.'
Although the law does recognize a parent's right to act on behalf of a
child,8" only a few states have statutorily extended that right to incompetent
parents and spouses, and the case law in only a couple of states would permit
such activity on behalf of an incompetent adult.82
The purpose of allowing a parent to exercise proxy consent for a child is
the preservation of that child's autonomy."3 Presumably, the good sense of
the parent will allow that child to mature so that he too can exercise the
autonomy of a competent adult.8 4 Obviously, that reason provides no basis
whatsoever for allowing an adult to consent on behalf of an incompetent
spouse, parent, or other relative. No one believes that one consenting to
77. Supra note 64.
78. Ratzan, supra note 13, at 38.
79. Rosoff, supra note 50. See also Annas, Glantz, & Katz, supra note 70; Turnbull, supra
note 52.
80. Rosoff, supra note 50, at 233-45.
81. Id. at 187-210.
82. Id. at 233-45. See also In re Storar, 52 N.Y.2d 363, 420 N.E.2d 64, 438 N.Y.S.2d 266
(1981); Farber v. Olkon, 40 Cal.2d 503, 254 P.2d 520 (1953); Lane v. Candura, 6 Mass. App.
377, 376 N.E. 2d 1232 (1978).
83. Rosoff, supra note 50, at 187-210.
84. Id.
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treatment for senile dementia is consenting to that treatment only so that the
patient will regain his full and competent abilities to exercise his unfettered
autonomy. For this reason, some have suggested that no proxy consent be
permitted for research." On the other hand, that would accomplish very
little. It would make some kinds of research - including research on those
severely ill with senile dementia - impossible, and it would deny to many
the opportunity to participate as a subject in an experiment just because they
are incompetent. The proposed but unadopted Regulations on Research In-
volving Those Institutionalized as Mentally Disabled suggest that under
some circumstances a "patient advocate" be able to exercise the power of
consent on behalf of an otherwise incompetent patient, at least where that
patient either "asserts" or does not apparently object to participation in the
research.86 Others may object to the definition of the "patient advocate"
because the term connotes someone who is an adversary to the medical au-
thorities, and those who object may prefer the term "patient surrogate." In
either case, the role of the one having authority to consent would be to deter-
mine whether the incompetent person, if competent, fully informed, and act-
ing without coercion, would consent to participation in the experiment.87 If
that person would do so then the advocate or surrogate would be able to
consent (or, alternatively, must consent) also.
CONCLUSION
The primary purpose of the doctrine of the informed consent is to protect
the autonomy of those who will receive medical treatment or will act as
research subjects. While the necessity of acquiring consent may impede
some types of research, the potential for investigator abuse of research sub-
jects warrants an informed consent requirement that is at least as restrictive
in a research context as it is in a purely therapeutic context.
The attributes found more frequently among elderly research subjects
than among younger subjects - congitive and emotional impairment, im-
paired vision and hearing, difficulty in resisting coercion, dependence on
family and health care providers, acceptance of non-mainstream values, in-
stitutionalization in nursing homes - require that the doctrine of compe-
tent, voluntary, informed consent be especially carefully applied in research
employing elderly subjects. While the precise requirements of competent,
voluntary, and informed consent will vary from protocol to protocol and
subject to subject, consent is more likely to be legally sound if (1) the sub-
85. Annas, Glantz & Katz, supra note 70, at 12.
86. See 43 Fed. Reg. 53,954, 45 C.F.R. § 46.5030) (1978).
87. See 43 Fed. Reg. 53,956, 45 C.F.R. § 46.506(a)(ii)(B) (1978).
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jects of a research protocol are not limited to the elderly if others could also
be employed as subjects without threatening the scientific integrity of the
research protocol; (2) in research involving Alzheimer's disease, those with
less severe dementia are preferred to those with more severe dementia as
research subjects; and (3) those outside of nursing homes are preferred to
those who are residents of nursing homes as research subjects.
The degree to which the preferences suggested here should be require-
ments depends on the value the community confers upon research among
the elderly, those institutionalized in nursing homes, and the senile, and how
important we view the protection of their autonomy to be. That balancing
can be conducted informally by researchers themselves, or more formally
through the explication of the common law of informed consent, the devel-
opment of formal hospital policies, or the promulgation of federal
regulations.

